Selected Publications:

1. **Eum S**, Hill SK, Bishop JR. Considering medication exposure in genomic association studies of cognition in psychotic disorders. Pharmacogenomics. 2022 Sep;23(14):791-806.
2. **Eum S**, Sayre F, Lee AM, Stingl JC, Bishop JR. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis. Pharmacotherapy. 2022 Jan;42(1):34-44.
3. **Eum S**, Hill SK, Alliey-Rodriguez N, Stevenson JM, Rubin LH, Lee AM, Mills LJ, Reilly JL, Lencer R, Keedy SK, Ivleva E, Keefe RSE, Pearlson GD, Clementz BA, Tamminga CA, Keshavan MS, Gershon ES, Sweeney JA, Bishop JR. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology. 2021 Sep;46(10):1802-1810.
4. **Eum S**, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Gershon ES, Keshavan MS, Keefe RS, Sweeney JA, Bishop JR. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017;190:129-135.
5. **Eum S**, Schneiderhan M, Brown JT, Lee A, Bishop JR. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. BMC Psychiatry. 2017;17(1):238.
6. **Eum S**, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci. 2016;18(3):323-337.